Deutsche Bank AG Invests $1.59 Million in Mineralys Therapeutics, Inc. $MLYS

Deutsche Bank AG purchased a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 58,877 shares of the company’s stock, valued at approximately $1,589,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. TimesSquare Capital Management LLC acquired a new position in Mineralys Therapeutics in the second quarter worth $6,363,000. Persistent Asset Partners Ltd bought a new position in shares of Mineralys Therapeutics in the second quarter valued at about $389,000. Bank of New York Mellon Corp bought a new position in shares of Mineralys Therapeutics in the second quarter valued at about $4,278,000. Walleye Capital LLC bought a new stake in Mineralys Therapeutics during the 2nd quarter worth about $271,000. Finally, Handelsbanken Fonder AB grew its holdings in Mineralys Therapeutics by 92.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 27,200 shares of the company’s stock worth $734,000 after acquiring an additional 13,100 shares during the last quarter. 84.46% of the stock is owned by institutional investors and hedge funds.

Mineralys Therapeutics Price Performance

Mineralys Therapeutics stock opened at $25.60 on Friday. The firm has a market capitalization of $2.26 billion, a P/E ratio of -6.04 and a beta of 0.68. Mineralys Therapeutics, Inc. has a 1 year low of $14.94 and a 1 year high of $47.65. The business has a 50-day moving average of $26.88 and a 200-day moving average of $27.17. The company has a current ratio of 34.46, a quick ratio of 34.46 and a debt-to-equity ratio of 0.18.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). On average, equities analysts anticipate that Mineralys Therapeutics, Inc. will post -4.45 EPS for the current year.

Insider Activity

In other Mineralys Therapeutics news, insider David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.09, for a total transaction of $58,785.30. Following the transaction, the insider directly owned 51,384 shares in the company, valued at approximately $1,391,992.56. The trade was a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total value of $1,960,500.00. Following the completion of the transaction, the chief executive officer directly owned 614,321 shares of the company’s stock, valued at approximately $16,058,350.94. The trade was a 10.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 224,333 shares of company stock valued at $5,806,213. 18.94% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Zacks Research cut shares of Mineralys Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen cut Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $49.33.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.